{
  "abstract": "After investing decades and billions of yuan in becoming a scientific superpower, China is well placed to benefit from the plight of the US medical research sector. But geopolitical ructions and local idiosyncrasies could complicate this, writes Flynn Murphy",
  "authors": [
    {
      "affiliations": [
        "Bangkok"
      ],
      "name": "Flynn Murphy"
    }
  ],
  "title": "How China became the new world leader in clinical trials",
  "uid": "80e23443-f843-520f-bb81-baf7cc34038c"
}